Transcriptomic and proteomic assessment of tocilizumab response in a randomized controlled trial of patients hospitalized with COVID-19

High interleukin (IL)-6 levels are associated with greater COVID-19 severity. IL-6 receptor blockade by tocilizumab (anti-IL6R; Actemra) is used globally for the treatment of severe COVID-19, yet a molecular understanding of the therapeutic benefit remains unclear. We characterized the immune profil...

Descripción completa

Detalles Bibliográficos
Autores principales: Shivram, Haridha, Hackney, Jason A., Rosenberger, Carrie M., Teterina, Anastasia, Qamra, Aditi, Onabajo, Olusegun, McBride, Jacqueline, Cai, Fang, Bao, Min, Tsai, Larry, Regev, Aviv, Rosas, Ivan O., Bauer, Rebecca N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470387/
https://www.ncbi.nlm.nih.gov/pubmed/37664617
http://dx.doi.org/10.1016/j.isci.2023.107597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470387/
https://www.ncbi.nlm.nih.gov/pubmed/37664617
http://dx.doi.org/10.1016/j.isci.2023.107597

Ejemplares similares